Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deutetrabenazine for Dysphagia in Huntington's Disease
NCT04301726Phase 1Terminated
- Sponsor
- Fundación Huntington Puerto Rico
- Start
- Jan 2022
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Huntington's disease (HD) comparing Deutetrabenazine with Placebo (2 arms). Primary endpoint: Change in swallow function/dysphagia at 18 months. Started Jan 2022; status: terminated.
02
Drugs
deutetrabenazine
03
Conditions
Huntington's disease (HD)
Beyond the preview
Go deeper on NCT04301726.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04301726.